1887

Abstract

Antibodies have been raised against a synthetic peptide (IRDKIQKENALFRNL) containing a neutralizing epitope within the second variable region of the human immunodeficiency virus type 1 (HIV-1) SF2 strain external envelope glycoprotein (gp120) and also against equivalent peptides of the HIV-1 LAI, RF and MN isolates. The resulting antisera cross-react with heterologous peptides but binding to heterologous recombinant gp120 is more restricted. Antisera to HIV-1 SF2, RF and MN are able to neutralize homologous virus. Some cross-neutralization is also observed, but a consensus peptide failed to induce neutralizing antibodies to any of the isolates studied. Antibodies to the V2 and V3 epitopes give a higher neutralization index when acting together than when the individual sera are used alone. Antibodies induced in natural infection bind to two sets of hexamers within the region encompassed by the 15-mer peptide, and the response to these can differ between infected individuals and within the same host over time.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-74-12-2609
1993-12-01
2022-08-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/74/12/JV0740122609.html?itemId=/content/journal/jgv/10.1099/0022-1317-74-12-2609&mimeType=html&fmt=ahah

References

  1. Barre-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vezinet-Bruin F., Rouzioux C., Rozenbaum W., Montagnier L. 1993; Isolation of a T-lymphotropic retrovirus from a patient at risk for aquired immune deficiency syndrome (AIDS). Science 220:868–871
    [Google Scholar]
  2. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. 1990; Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gpl60. Nature, London 345:622–625
    [Google Scholar]
  3. Blattner W. A. 1991; HIV epidemiology past, present and future. FASEB Journal 5:2340–2348
    [Google Scholar]
  4. Cheng-Mayer C., Levy J. 1988; Distinct biological and serological properties of human immunodeficiency viruses from the brain. Annals of Neurology 23:S58–S61
    [Google Scholar]
  5. Cheng-Mayer C., Homsy J., Evans L. A., Levy J. A. 1988; Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proceedings of the National Academy of Sciences, U.S.A 85:2815–2819
    [Google Scholar]
  6. Cranage M. P., Baskerville A., Ashworth L. A. E., Dennis M., Cook N., Sharpe S., Farrar G., Rose J., Kitchin P. A., Greenaway P. J. 1992; Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet 339:273–274
    [Google Scholar]
  7. Davis D., Chaudhri B., Stephens D. M., Carne C. A., Willers C., Lachmann P. J. 1990a; The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host’s previous exposure to similar epitopes on unrelated antigens. Journal of General Virology 71:1975–1983
    [Google Scholar]
  8. Davis D., Stephens D. M., Willers C., Lachmann P. J. 1990b; Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. Journal of General Virology 71:2889–2898
    [Google Scholar]
  9. Fung M. S. C., Sun C. R. Y., Gordon W. L., Liou R.-S., Chang T. W., Sun W. N. C., Daar E. S., Ho D. D. 1992; Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. Journal of Virology 66:848–856
    [Google Scholar]
  10. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B., White G., Foster P., Markham P. D. 1984; Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500–503
    [Google Scholar]
  11. Gill T. J., Kunz H. W., Friedman E., Doty P. 1963; Studies on synthetic polypeptide antigens. VIII. The inhibition of the antibody-synthetic polypeptide reaction by amino acids, dipeptides, amines, alcohols, and dicarboxylic acids. Journal of Biological Chemistry 238:108–123
    [Google Scholar]
  12. Girard M., Kieny M.-P., Pinter A., Barre-Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E., Ronco J., Kacsorek M., Gomard E., Gluckman J. C., Fultz P. N. 1991; Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, U,. S,. A 88:542–546
    [Google Scholar]
  13. Haigwood N. L., Barker C. B., Higgins W. K., Skiles P. V., Moore G. K., Mann K. A., Lee D. R., Eichberg J. W. 1990; Evidence for neutralizing antibodies directed against conformational epitopes of HIV-1 gp120. In Vaccines 90 pp 313–320 Edited by Brown F., Chanock R. M., Ginsberg H., Lerner R. A. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  14. Harada S., Kobayashi N., Koyanagi Y., Yamamoto N. 1987; Clonal selection of human immunodeficiency virus (HIV): serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-IIIB, LAV, and ARV). Virology 158:447–151
    [Google Scholar]
  15. Ho D. D., Schooley R. T., Rota T. R., Kaplan J. C., Flynn T., Salahuddin S. Z., Gonda M. A., Hirsch M. C. 1984; HTLV-III in the semen and blood of a healthy homosexual man. Science 226:451–153
    [Google Scholar]
  16. Ho D. D., Kaplan J. C., Rackauskas I. E., Gurney M. E. 1988; Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 239:1021–1023
    [Google Scholar]
  17. Holmberg S. D., Horsburgh C. R., Ward J. W., Jaffe H. W. 1989; . Biologic factors in the sexual transmission of human immunodeficiency virus. Journal of Infectious Diseases 160:116–125
    [Google Scholar]
  18. Krieger J. N., Coombs R. W., Collier A. C., Ross S. O., Chalpouka K., Cummings D. K., Murphy V. L., Corey L. 1991; Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral therapy. Journal of Infectious Diseases 163:386–388
    [Google Scholar]
  19. Leonard C. K., Spellman M. W., Riddle L., Harris R. J., Thomas J. N., Gregory T. J. 1990; Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. Journal of Biological Chemistry 265:10373–10382
    [Google Scholar]
  20. Levy J. A., Hoffman A. D., Kramer S. M., Landis J. A., Shimabukuro J. M., Oshiro L. S. 1984; Isolation of lympho-cytopathic retroviruses from San Francisco patients with AIDS. Science 225:840–842
    [Google Scholar]
  21. Levy J. A., Kaminsky L. S., Morrow W. J. W., Steimer K., Luciw P., Dina D., Hoxie J., Oshiro L. 1986; Infection by the retrovirus associated with the acquired immunodeficiency syndrome. Clinical, biological, and molecular features. Annals of Internal Medicine 103:694–699
    [Google Scholar]
  22. McCullough K. C. 1986; Monoclonal antibodies: implications for virology. Archives of Virology 87:1–36
    [Google Scholar]
  23. McKeating J. A., McKnight A., Moore J. P. 1991; Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. Journal of Virology 65:852–860
    [Google Scholar]
  24. Mann D. L., O’Brien S. J., Gilbert D. A., Reid Y., Popovic M., Read-Connole E., Gallo R. C., Gazdar A. F. 1989; Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Research and Human Retroviruses 5:253–255
    [Google Scholar]
  25. Moore J. P., McKeating L. A., Weiss R. A., Sattentau Q. J. 1989; Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139–1142
    [Google Scholar]
  26. Neurath A. R., Strick N., Lee E. S. Y. 1990; B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides. Journal of General Virology 71:85–95
    [Google Scholar]
  27. Popovic M., Sarnagadharan M. G., Read E., Gallo R. C. 1984; Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and preAIDS. Science 224:497–500
    [Google Scholar]
  28. Ratner L., Haseltine W., Patarca R., Livak K. J., Starcich B., Josephs S. F., Doran E. R., Rafalski A., Whitehorn E. A., Baumeister K., Ivanoff L., Petteway S. R., Pearson M. L., Lautenburger J. A., Papas T. S., Ghrayeb J., Chang N. T., Gallo R. C., Wong-Staal F. 1985; Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature, London 313:277–284
    [Google Scholar]
  29. Salahuddin S. Z., Markham P. D., Wong-Staal F., Franchini G., Kalyanaraman V. S., Gallo R. C. 1983; Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology 129:51–64
    [Google Scholar]
  30. Sanchez-Pescador R., Power M. D., Barr B. J., Steimer K. S., Stempien M. M., Brown-Shimmer S. L., Gee W. W., Renard A., Randolph A., Levy J. A., Dina D., Luciw P. A. 1985; Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 227:484–492
    [Google Scholar]
  31. Spence R. P., Jarvill W. M., Ferns R. B., Tedder R. S., Parker D. 1989; The cloning and expression in Escherichia coli of sequences coding for p24, the core protein of human immunodeficiency virus, and the use of the recombinant protein in characterizing a panel of monoclonal antibodies against the viral p24 protein. Journal of General Virology 70:2843–2851
    [Google Scholar]
  32. Steimer K. S., van Nest G. A., Haigwood N. L., Tillson E. M., George-Nascimento C., Barr P. J., Dina D. 1988; Recombinant env and gag polypeptides in characterizing HIV-1-neutralizing antibodies. In Vaccines 88 pp 347–355 Edited by Ginsberg H., Brown F., Lerner R. A., Chanock R. M. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  33. Stephens D. M., Eichberg J. W., Haigwood N. L., Steimer K. S., Davis D., Lachmann P. J. 1992; Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. Journal of General Virology 73:1099–1106
    [Google Scholar]
  34. Sutjipto S., Pedersen N. C., Miller C. J., Gardner M. B., Hanson C. V., Gettie A., Jennings M., Higgins J., Marx P. A. 1990; Inactivated simian immunodeficiency virus failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. Journal of Virology 64:2290–2297
    [Google Scholar]
  35. Thali M., Furman C., Wahren B., Posner M., Ho D. D., Robinson J., Sodroski J. 1992; Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. Journal of Acquired Immune Deficiency Syndromes 5:591–599
    [Google Scholar]
  36. Tilley S. A., Honnen W. J., Racho M. E., Chou T.-C., Pinter A. 1992; Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD-4 binding site of gp120. AIDS Research and Human Retroviruses 8:461–467
    [Google Scholar]
  37. Tisdale M., Ertl P., Larder B. A., Purifoy D. J. M., Darby G., Powell K. L. 1988; Characterization of human immunodeficiency virus type 1 reverse transcriptase by using monoclonal antibodies: role of the C terminus in antibody reactivity and enzyme function. Journal of Virology 62:3662–3667
    [Google Scholar]
  38. Vogt M. W., Witt D. J., Craven D. E., Byington R., Crawford D. F., Schooley R. T., Hirsch M. S. 1986; Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet i:525–527
    [Google Scholar]
  39. Wain-Hobson S., Vartanian J.-P., Henry M., Chenciner N., Cheynier R., Delassus S., Martins L. P., Sala M., Nugeyre M.-T., Guetard D., Klatzmann D., Gluckman J.-C., Rozenbaum W., Barre-Sinoussi F., Montagnier L. 1991; LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. Science 252:961–965
    [Google Scholar]
  40. Weiss R. A., Clapham P. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. 1986; Variable and conserved neutralization antigens of human immunodeficiency virus. Nature, London 324:572–575
    [Google Scholar]
  41. Wofsy C. B., Cohen J. B., Hauer L. B., Padian N. S., Michaelis A. A., Evans L. A., Levy J. A. 1986; Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet i:527–529
    [Google Scholar]
  42. Zagury D., Bernard J., Liebowitch J., Safai B., Groopman J. E., Feldman M., Sarngadharan M. G., Gallo R. C. 1984; HTLV-III in cell cultures from the semen of two patients with AIDS. Science 226:449–451
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-74-12-2609
Loading
/content/journal/jgv/10.1099/0022-1317-74-12-2609
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error